DXC 006
Alternative Names: DXC-006Latest Information Update: 15 Jun 2024
At a glance
- Originator Hangzhou DAC Biotech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 08 Apr 2024 Pharmacodynamic and adverse event data from a preclinical study in Lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 24 Jan 2024 Hangzhou DAC Biotechnology plans a first-in-human phase I trial for Solid tumours and Haematological malignancies (Late-stage disease, Second-line therapy or greater) (IV) in January 2024 (NCT06224855)
- 02 Jun 2022 Preclinical trials in Lung cancer in China (Parenteral) before June 2022 (Hangzhou DAC Biotech pipeline, June 2022)